Infinimmune, a San Francisco, CA-based biotechnology company, raised $12M in Seed funding.
The round was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier.
The company intends to use the funds to expand team of talent, develop R&D capabilities, and scale operations.
Founded by Wyatt McDonnell, Katie Pfeiffer, Mike Gibbons, Lance Hepler, and David Jaffe, Infinimmune is a biotechnology company with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These human antibodies are designed to drug new and existing targets with improved safety and efficacy.
Infinimmune will deploy its holistic approach to build its own pipeline of drug candidates and partner with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications.